RR

Rajiv Ranjan

Active Director Director DIN 08089580
DIN 08089580 First appointment Apr 2018 Primary industry Trading
Unlock full profile Investments · shareholding · contact details
Current companies 1 active board seats
Total affiliations 1 Since Apr 2018
Shareholding value •••• Premium profile

About Rajiv Ranjan

Data last updated:

Rajiv Ranjan is a Director at Cranio Pharma Private Limited (since 2018). The company operates in Trading. Cranio Pharma Private Limited reported revenue of ₹2.8 Lakh (FY 2023).

DIN 08089580
Primary Designation Director
Industry Trading
First Appointment 09 Apr 2018
Oldest Company Age 8 yrs
Largest company Cranio Pharma Private Limited · ₹2.8 Lakh (FY 2023)

Current companies

CompanyDesignationAppointmentFoundedRevenueStatus
Cranio Pharma Private Limited U51909MH2018PTC307717
Director09 Apr 20182018₹2.8 Lakh (FY 2023)Active

Board colleagues of Rajiv Ranjan

Directorship timeline

Open interactive timeline →
Cranio Pharma Private Limited
Premium access

Shareholding and investment profile for Rajiv Ranjan

Company-level share counts, filed values, and quarterly changes require authenticated premium access.

  • Company-level holdings
  • Filed share counts
  • Reported values
  • Quarterly changes
Unlock shareholding

Verified entity values are shown only after access is granted.

Frequently Asked Questions about Rajiv Ranjan

Rajiv Ranjan currently holds 1 directorship: Cranio Pharma Private Limited (Director, since 09 Apr 2018, revenue ₹2.8 Lakh (FY 2023)).

Rajiv Ranjan was first appointed on 09 Apr 2018 as Director at Cranio Pharma Private Limited.

The current boards of Rajiv Ranjan's companies include Kanchan Jha Kishan (Cranio Pharma Private Limited), Neeraj Kumar (Cranio Pharma Private Limited), Pawan Kumar (Cranio Pharma Private Limited).

Explore millions of companies — effortlessly

Access structured, verified intelligence on 7M+ companies across industries, sectors, and global markets. From early-stage startups to large enterprises, discover ownership, leadership, funding, financials, acquisitions, and market signals — all in one powerful platform.

Free account with essential features Instant access to company reports Enterprise solutions available